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Abstract
Osteoporosis is defined as a “generalized skeletal disorder characterized by compromised
bone strength and deterioration of bone quality, often leading to fragility fracture” (DynaMed
Plus, 2018). The prevalence of osteoporosis in the United States in adults aged greater than or
equal to 50 years of age is “more than 10 million people overall and 33 million have low bone
mineral density at the hip” (DynaMed Plus, 2018). Of these affected, one in two women will
experience an osteoporotic fracture in their lifetime (International Osteoporosis Foundation,
2017). To combat postmenopausal osteoporosis, two treatment options include bisphosphonates
and the anti-receptor activator of nuclear factor kappa β ligand (RANKL) agent. The purpose of
this scholarly project is to determine if there is a statistical significance regarding safety,
efficacy, and preference between bisphosphonates and the anti-RANKL agent due to different
mechanisms of action. Three databases were searched: PubMed, CINAHL, and Cochrane
Database of Systematic Reviews. Topics researched included: postmenopausal osteoporosis,
bisphosphonates, anti-RANKL agent, treatment outcome, adverse effects, and efficacy. Research
was conducted from September 12, 2018 to January 29, 2019. All works were published within
the last 10 years. Limitations and strengths were considered within each modality. The most
effective treatment for postmenopausal osteoporosis is the anti-RANKL agent. It is just as safe,
more efficacious, better adhered to, and more preferred than bisphosphonates. This scholarly
project compares the treatment options available to providers and allows them to choose the best
treatment option based on the patient’s needs, safety, efficacy, preference, and cost.
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Comparison of Pharmacologic Treatments for Postmenopausal Osteoporosis
Introduction
Osteoporosis is defined as a “generalized skeletal disorder and is characterized by
compromised bone strength and deterioration of bone quality, often leading to fragility fracture”
(DynaMed Plus, 2018). This most often affects women greater than or equal to 65 years of age,
Asian and Caucasian descents, and those with a small body frame. The prevalence of
osteoporosis in the United States in adults aged greater than or equal to 50 years of age is “more
than 10 million people overall and 33 million have low bone mineral density (BMD) at the hip”
(DynaMed Plus, 2018). Of these affected, one in two women will experience an osteoporotic
fracture in their lifetime (International Osteoporosis Foundation, 2017). For women, this
incidence is greater than breast cancer, heart attack, and stroke combined; therefore, it is one of
the leading public health problems (International Osteoporosis Foundation, 2017).
To comprehend osteoporosis and low BMD, the bone remodeling process in healthy
bones must be understood. In healthy bones, bone formation by osteoblast cells is in balance
with bone resorption by osteoclast cells. This process is maintained in normal bones throughout
life. However, when bone resorption by the osteoclast cells outpaces bone formation by the
osteoblast cells, the result is bone loss. The decrease in bone mass leads to an increase in fracture
risk. Fractures occur when the weak bones are overloaded.
Two forms of osteoporosis exist: primary and secondary. Primary osteoporosis is the
result of aging and sex steroid deficiency. The sex steroid particularly deficient is 17betaestradiol in menopause women (DynaMed Plus, 2018). This sex steroid inhibits bone resorption
without increasing bone formation. Secondary osteoporosis is the result of multiple causes and
risk factors. These include, but are not limited to, low calcium intake, low vitamin D intake,
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glucocorticoid use, long-term anticoagulation use, long-term proton pump inhibitor use,
hormonal therapies, inadequate physical activity, alcohol use, tobacco use, and genetic factors
(DynaMed Plus, 2018). Due to the postmenopausal interest of this scholarly project, primary
osteoporosis will be the focus.
To combat postmenopausal osteoporosis, two common treatments include
bisphosphonates and the anti-receptor activator of nuclear factor kappa β ligand (RANKL) agent.
The mechanism of action (MOA) varies between these two classes. Bisphosphonates inhibit
bone resorption by osteoclasts which decreases bone turnover. The anti-RANKL agent binds to
receptor activator of nuclear kappa-β ligand, which inhibits osteoclast formation and reduces
bone resorption and turnover.
Therefore, the purpose of this scholarly project is to determine if there is a statistical
significance regarding safety, efficacy, and preference between bisphosphonates and the antiRANKL agent due to differing MOAs.
Statement of the Problem
The United States Food and Drug Administration (U.S. FDA) approved the first
bisphosphonate for the treatment of postmenopausal osteoporosis in 1995 (Food and Drug
Administration, n.d.). The U.S. FDA approved the first anti-RANKL agent for the treatment of
postmenopausal osteoporosis in 2010 (Food and Drug Administration, n.d.). Fifteen years
separated the approval of each treatment option for postmenopausal osteoporosis. In those years,
countless amounts of research was completed on bisphosphonates for their safety and efficacy
and now similar research is being completed on the anti-RANKL agent. The American
Association of Clinical Endocrinologists approved both bisphosphonates and the anti-RANKL
agent as first-line treatment (Camacho, 2016). This scholarly project analyzes both
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bisphosphonates and the anti-RANKL agent that have been heavily researched to determine the
safest and most efficacious treatment. However, with differing MOAs, one treatment option may
be statistically superior. This scholarly project will uncover if there is a statistical significance
between treatments regarding safety, efficacy, and preference. Providers need to be informed on
the latest research to provide their patients with optimal first-line treatment for postmenopausal
osteoporosis.
Research Question
In the treatment of postmenopausal osteoporosis, is there a statistical difference in the
safety, efficacy, and preference when using bisphosphonates versus the anti-RANKL agent?
Methods
For this scholarly project, three databases were searched, which included PubMed,
CINAHL, and Cochrane Database of Systematic Reviews, from September 12, 2018 to January
29, 2019. PubMed database was the primary resource for researching postmenopausal
osteoporosis treatment. Subject headings included “Osteoporosis, Postmenopausal" [Major],
“Diphosphonates” [Mesh], “Denosumab” [Mesh], “RANK Ligand” [Mesh],
"Diphosphonates/adverse effects" [Mesh], "Denosumab/adverse effects" [Mesh], “Treatment
Outcome” [Mesh], "Bone Density Conservation Agents" [Pharmacological Action]. The
CINAHL database subject headings included “Postmenopausal Osteoporosis” [MH],
“Treatment” [MH], and “Efficacy” [MH]. The Cochrane Systematic Review database was
searched with “Postmenopausal osteoporosis treatment.” To further refine the search, “AND”
and “OR” were used between subject heading. Inclusion criteria for this scholarly project
included meta-analysis, systematic reviews, and randomized control trials (RCTs). All works
were published within the last 10 years and written in the English language.
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Literature Review
Theme 1: Safety of Bisphosphonates
In theme one, safety of bisphosphonates, three studies were reviewed. Safety profiles
were investigated for the historic first line treatment, bisphosphonates. This theme studies
different safety measures of the most common bisphosphonates available for treatment of
postmenopausal osteoporosis.
Wang (2017) conducted a meta-analysis on the safety of zoledronic acid for the treatment
of postmenopausal osteoporosis utilizing a placebo-used approach. The meta-analysis included
eight RCTs (n= 13,355), a target population of women with postmenopausal osteoporosis,
treatment with zoledronic acid (five milligrams (mg) intravenous (IV)), and a secondary endpoint of safety. The results of the incidence of any adverse events (AEs) in the zoledronic acid
group and placebo group were 91.9% and 90.3%, respectively (Wang, 2017). Using a fixedeffect model, this resulted in participants receiving zoledronic acid having a significantly higher
incidence of any AEs than those receiving placebo (risk ratio (RR) 1.02 (1.01-1.03), 95%
confidence interval (CI), p = 0.000) (Wang, 2017). The incidences of any serious adverse events
(SAEs) in the zoledronic acid group and placebo group were 30.0% and 31.2%, respectively
(Wang, 2017). Using a fixed-effect model, this resulted in no significant difference between the
two groups (RR 0.96 (0.92-1.01), 95% CI, p = 0.087) (Wang, 2017). The most frequent AEs
included first-dose acute-phase reaction such as pyrexia, myalgia, arthralgia, headache, chills,
and influenza-like symptoms (Wang, 2017).
Wang (2017) declared no conflict of interest. This is significant because it demonstrates
there is no bias towards treatment versus placebo. However, he highlighted several limitations
which included substantial heterogeneity, small sample size, and variable duration of follow-up
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(Wang, 2017). Overall, Wang (2017) is significant because it establishes the foundation for the
safety of bisphosphonates, specifically zoledronic acid, to treat women with postmenopausal
osteoporosis.
Researchers Eriksen, Diez-Perez, and Boonen (2014) explored the latest long-term safety
data of bisphosphonate treatment for the management of postmenopausal osteoporosis. Nine
primary articles were included in this systematic review. Bisphosphonates were compared to
placebo, and the bisphosphonates under investigation included alendronate, risedronate,
ibandronate (oral), and zoledronic acid. For alendronate (alendronate for 10 years (n= 553) and
alendronate for five years followed by placebo for five years (n= 361)), no significant differences
between the groups in the incidence of AEs, upper gastrointestinal AEs, SAEs, or
discontinuation due to AEs were reported (Eriksen et al., 2014). For risedronate (risedronate for
five years (n= 130) and placebo for five years (n= 135)), five years of treatment was associated
with similar rates of AEs, SAEs, and discontinuation due to AEs as placebo (9.6 versus 8.6%)
(Eriksen et al., 2014). For ibandronate (n= 309), gastrointestinal AEs were reported in 1.7 to
7.4% of participants and were the most common AEs reported (Eriksen et al., 2014). For
zoledronic acid (zoledronic acid for six years (n= 450) and zoledronic acid for three years
followed by placebo for three years (n= 467)), there was comparable incidence of AEs, SAEs,
and deaths between participants who had received treatment for six years and those who
discontinued treatment after three years (Eriksen et al., 2014). The results concluded no
unexpected AEs developing from long-term use of any of the bisphosphonates for the treatment
of postmenopausal osteoporosis (Eriksen et al, 2014).
Overall, Eriksen et al. (2014) is significant because of the long-term trials. Safety
analyses are of paramount importance because not all possible safety concerns can be identified
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during initial short-term trials (Eriksen et al., 2014). However, the main limitation was the lack
of statistical analyses for the overall AEs and SAEs regarding the long-term safety of
bisphosphonates. Confidence intervals, risk ratios, and p-values were not recorded for this area
of research. Also, the heterogeneity between groups was pronounced between populations,
interventions, lengths of follow-up and drugs tested which lead to no formal meta-analysis
(Eriksen et al., 2014).
Lin et al. (2012) conducted a meta-analysis to compare the safety profiles between the
anti-RANKL agent (denosumab) and the bisphosphonate (alendronate) in postmenopausal
osteoporosis. The meta-analysis included four RCTs each with a double-blinded and placebobased approach. Each trial had a target population of women with postmenopausal osteoporosis
and results included safety profiles of each treatment. The treatments were 60 mg of denosumab
subcutaneous (SC) injections every six months or 70 mg orally (PO) of alendronate weekly.
Results showed similar safety profiles at the one-year follow-up (Lin et al., 2012). Total AEs
were 14 fewer per 1000 with denosumab treatment (odds ratio (OR) 0.91 (0.72-1.15), 95% CI,
p = 0.66) (Lin et al., 2012). SAEs were 61 fewer per 1000 with denosumab treatment (OR 0.91
(0.63-1.33), 95% CI, p = 0.65) (Lin et al., 2012). Neoplasms were three more per 1000 with
denosumab treatment (OR 1.10 (0.62-1.86), 95% CI, p = 0.62) (Lin et al., 2012). Infections were
12 fewer per 1000 with denosumab treatment (OR 0.95 (0.76-1.15), 95% CI, p = 0.62) (Lin et
al., 2012). Therefore, the meta-analysis provided low to very low evidence that denosumab SC
every six months could neither reduce the risk of AEs and SAEs nor increase the risk of
neoplasms and infections compared with alendronate PO weekly (Lin et al., 2012).
The researchers assured their funding sources were independent and had no influence
when publishing their findings (Lin et al., 2012). This is significant because it demonstrates there
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was no bias towards either treatment. Limitations included failure to follow-up leading to
incomplete outcome data in some trials, substantial heterogeneity, observational duration of only
one-year, only four trials were included, and all included studies were sponsored by the
pharmaceutical company related to denosumab (Lin et al., 2012). Overall, having a direct
comparison of the safety of current first line treatment, bisphosphonates, to the upcoming
treatment option, denosumab, makes this a foundational study.
Theme 2: Safety of the anti-RANKL agent
In theme two, safety of the anti-RANKL agent (denosumab), four studies were reviewed.
This theme investigates the safety profile of denosumab, an upcoming treatment option for
treatment of postmenopausal osteoporosis.
Researches Bone et al. (2008) evaluated the safety of denosumab versus placebo over 24
months with a randomized, double-blind, phase III study. The target population included women
with a lumbar spine BMD T-score between -1.0 and -2.5 (Bone et al., 2008). The participants
were assigned to receive either 60 mg denosumab SC every six months or placebo for two years
(denosumab (n= 116) and placebo (n= 116)) (Bone et al., 2008). In the denosumab group, one
participant discontinued due to AEs and in the placebo group, two participants discontinued due
to AEs (Bone et al., 2008). The results of the overall incidence of AEs over 24 months was
similar between the denosumab (60%) and placebo (61%) groups (Bone et al., 2008). SAEs were
reported for 18 participants in the denosumab group (11%) and nine participants in the placebo
group (5.55%) (p = 0.074) (Bone et al., 2008). Neoplasms were reported in four participants in
the denosumab group and one participant in the placebo group (p = 0.215) (Bone et al., 2008).
No deaths occurred during the study (Bone et al., 2008).
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The main limitation was the briefness of the safety analysis because the primary focus of
the study was to report the efficacy which will be discussed in theme four. Overall, Bone et al.
(2008) is a significant addition to the foundation of the safety of denosumab.
Researchers Keyserlingk et al. (2011) assessed the safety of offering denosumab in
postmenopausal women with low BMD. Keyserlingk et al. (2011) included four RCTs and the
results included the safety and incidence of SAEs (infection, neoplasms, and percentage of
discontinuation due to AEs). The SAEs of denosumab compared to placebo were statistically
insignificant (RR 1.33 (0.8-2.14), 95% CI) (Keyserlingk, 2011). The SAEs related to infection of
denosumab compared to placebo were statistically insignificant (RR 2.10 (0.64 to 6.90), 95% CI)
(Keyserlingk, 2011). The SAEs related to neoplasm of denosumab compared to placebo were
statistically insignificant (RR 1.11 (0.91 to 1.36), 95% CI) (Keyserlingk, 2011). The
discontinuation due to AEs of denosumab compared to placebo were statistically insignificant
(RR 1.10 (0.83 to 1.47), 95% CI) (Keyserlingk, 2011). The incidence of death of denosumab
compared to placebo was statistically insignificant (RR 0.78 (0.57 to 1.06), 95% CI)
(Keyserlingk, 2011). Overall, there was no significant increase in relative SAEs in participants
on denosumab compared to placebo.
The limitations include heterogeneity between sample sizes and variable participant
characteristics. However, a major strength is the inclusion of only RCTs that treated thousands of
participants with denosumab. This illustrates very strong evidence for the safety of denosumab.
Researcher Deeks (2018) summarized the relevant data of denosumab for the treatment of
postmenopausal osteoporosis. Deeks (2018) highlighted the long-term safety of denosumab by
selecting phase III and IV trials. The most comprehensive information came from the three-year
phase III trial FREEDOM (n= 7,808) and its seven-year extension (n= 4,550). The FREEDOM
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trial is the focus of the results section due to its number of participants. The other trials used by
Deeks (2018) to support his research included DECIDE (n= 1,179), STAND (n= 504), Recknor
et al. (n= 833), Roux et al. (n= 870), and Miller et al. (n= 643). The results declared 60 mg
denosumab SC every six months was well tolerated for up to 10 years in postmenopausal women
with low BMD and most AEs were mild to moderate (Deeks, 2018). Over the initial three-year
study, denosumab did not significantly differ from placebo in percentage of treatment-emergent
adverse events (TEAEs) (93 versus 93%), serious TEAEs (26 versus 25%), death (1.8 versus
2.3%), or discontinuation of treatment because of TEAEs (4.9 versus 5.2%) (Deeks, 2018). The
TEAEs that were statistically significant in denosumab versus placebo include eczema (3.0
versus 1.7%) and flatulence (2.2 versus 1.4%) (p < 0.01) (Deeks, 2018). Whereas, the TEAEs
that were statistically significant in placebo versus denosumab include non-fracture related falls
(4.5 versus 5.7%) (p = 0.02) (Deeks, 2018). The serious TEAEs that were statistically significant
included cellulitis (0.3 versus <0.1%) and concussion (<0.1 versus 0.3%) (p < 0.005) (Deeks,
2018). There was no statistical difference between the incidence of infection, cancer, or delayed
fracture healing between denosumab and placebo (Deeks, 2018). In terms of the overall
incidence of AEs of denosumab compared to bisphosphonates, TEAEs (60-81 versus 56-82%),
TEAEs leading to discontinuation (1-2 versus 1-4%), death (< 0.4 versus < 0.3%), or serious
TEAEs (6-8 versus 6-9%) were reported (Deeks, 2018). Looking at select AEs, denosumab did
not significantly differ from alendronate or ibandronate in the incidence of infections, neoplasms,
or fractures (Deeks, 2018). However, statistically significant value occurred in denosumab versus
ibandronate with serious TEAEs (10 versus 5%) (p < 0.05) (Deeks, 2018). Other statistically
significant values of denosumab versus ibandronate include gastrointestinal (1.2 versus 0.2%)
and respiratory disorders (1.2 versus 0%) (Deeks, 2018). The last statistically significant value
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occurred in denosumab compared to zoledronic acid AEs of musculoskeletal pain (13 versus
20%) (p < 0.05) (Deeks, 2018).
The limitations include heterogeneity between studies, specifically regarding sample size.
Additionally, during the peer review process, the manufacturer of denosumab was offered the
opportunity to review this article; however, any changes made were claimed to be made based on
scientific and editorial merit (Deeks, 2018). Overall, Deeks (2018) compares the safety of
denosumab against not only placebo but also bisphosphonates which specifically addresses the
research question at hand.
Zhou et al. (2014) assessed the safety of denosumab in postmenopausal women with
osteoporosis or low BMD. Zhou et al. (2014) included 11 RCTs to compare the safety of
denosumab to bisphosphonates and placebo which included any adverse events (AAEs) and
SAEs related to infection, neoplasm, non-vertebral fracture, and death. No significant difference
between denosumab compared to placebo was demonstrated in AAEs (RR of 0.99 (0.98-1.01),
95% CI, and p = 0.29), SAEs (RR of 1.05 (0.98-1.13), 95% CI, and p = 0.18), neoplasms (RR of
1.14 (0.95-1.37), 95% CI, and p = 0.16), and deaths (RR of 0.77 (0.57-1.04), 95% CI, and p =
0.09) (Zhou et al., 2014). However, participants assigned to denosumab compared to placebo did
show a statistically significant risk for SAE related to infection (RR of 1.23 (1.00-1.52), 95% CI,
and p = 0.05) (Zhou et al., 2014). Furthermore, denosumab compared to bisphosphonates
indicated no statistically significant evidence to prove the difference in AAEs (RR of 0.98 (0.951.02), 95% CI), SAEs (RR of 1.06 (0.84-1.34), 95% CI), SAEs related to infection (RR of 1.13
(0.63-2.03), 95% CI), neoplasms (RR of 1.17 (0.73-1.87), 95% CI), non-vertebral fracture (RR
of 1.31 (0.87-1.98), 95% CI), and death (RR of 0.72 (0.20-2.59), 95% CI) (Zhou et al., 2014).
Overall, based on the results of the statistical analysis, there were no significant differences in

PHARM TREATMENTS FOR POSTMENOPAUSAL OSTEOPOROSIS

16

AAEs, SAEs, neoplasms, or death. However, statistical significance did arise in the risk of
infection for denosumab compared to placebo, but this finding was not consistent with
denosumab compared to bisphosphonates.
The main limitation was small sample size in all studies, except one. Zhou et al. (2014)
continues to advocate the safety of denosumab compared to placebo and the current first line
treatment, bisphosphonates.
Theme 3: Efficacy of Bisphosphonates
In theme three, efficacy of bisphosphonates, three studies were reviewed. This theme
investigates the changes in BMD and the fracture risk of bisphosphonates.
Wang (2017) conducted a meta-analysis on the efficacy of zoledronic acid for the
treatment of postmenopausal osteoporosis with a placebo-used approach. The meta-analysis
included eight RCTs (n= 13,355), a target population of women with postmenopausal
osteoporosis, and treatment with zoledronic acid (five mg IV). Primary end-points included
vertebral fracture, non-vertebral fracture, and hip fracture. Non-vertebral fracture incidence with
zoledronic acid was 5.4% versus placebo which was 7.5%, and when using a fixed-effect model,
zoledronic acid significantly reduced the incidence of non-vertebral fracture compared to
placebo (RR 0.75 (0.67-0.83), 95% CI, p = 0.000) (Wang, 2017). Vertebral fracture incidence
with zoledronic acid was 3.4% versus placebo which was 7.9%, and when using a fixed-effect
model, zoledronic acid significantly reduced the incidence of non-vertebral fracture compared to
placebo (RR 0.43 (0.34-0.53), 95% CI, p = 0.000) (Wang, 2017). Hip fracture incidence with
zoledronic acid was 2.3% versus placebo which was 2.9%, and when using a fixed-effect model,
zoledronic acid significantly reduced the incidence of non-vertebral fracture compared to
placebo (RR 0.76 (0.61-0.96), 95% CI, p = 0.020) (Wang, 2017). The effect of BMD at the
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lumbar spine with zoledronic acid was associated with a significant increase compared to
placebo (weighted mean difference (WMD) 3.76 (0.95-6.56), 95% CI, p = 0.009) (Wang, 2017).
The effect of BMD using zoledronic acid was associated with a significant increase compared to
placebo at the total hip (WMD 3.89 (2.52-5.26), 95% CI, p = 0.000), femoral neck (WMD 3.51
(2.37-4.65), 95% CI, p = 0.000), and trochanter (WMD 4.12 (1.56-6.68), 95% CI, p = 0.002)
(Wang, 2017). Overall, treatment with zoledronic acid significantly reduced the risk of fractures
and increased BMD for postmenopausal women with osteoporosis (Wang, 2017).
Wang (2017) addressed several limitations which included substantial heterogeneity,
small sample size, and duration of follow-up varied from 12 months to 36 months (Wang, 2017).
However, Wang (2017) is beneficial because it identifies the efficacy of zoledronic acid to treat
women suffering from postmenopausal osteoporosis.
Researchers Eriksen, Diez-Perez, and Boonen (2014) explored the latest long-term
efficacy data of bisphosphonate treatment for the management of postmenopausal osteoporosis.
Nine primary articles were included in this systematic review. Bisphosphonates were compared
to placebo, and the bisphosphonates under investigation included alendronate, risedronate,
ibandronate (oral), and zoledronic acid. The results concluded long-term use of bisphosphonates
in postmenopausal women had persistent beneficial effects on fracture risk and BMD beyond
three years of treatment (Eriksen et al., 2014). For alendronate, the study compared the effect of
10 years of continuous treatment (n= 662) versus five years of treatment followed by five years
of placebo (n= 437). Continuous treatment showed significantly lower risk of vertebral fracture
versus those who discontinued treatment (2.4 versus 5.3%, 95% CI, RR 0.45 (0.24-0.85))
(Eriksen et al., 2014). However, discontinuation of treatment did not seem to increase the risk of
non-vertebral or morphometric vertebral fractures (Eriksen et al., 2014). Results found that five
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additional years of treatment sustained BMD at the total hip, femoral neck, trochanter, lumbar
spine, total body and forearm compared with five years of placebo (p < 0.001) (Eriksen, et al.,
2014). For risedronate, the study compared five years of continuous treatment (n= 135) versus
three years of treatment followed by two years of placebo (n= 130). Continuous treatment
showed a vertebral fracture risk reduction of 59% versus those who discontinued treatment (95%
CI, p = 0.01) (Eriksen et al., 2014). Results regarding BMD indicated two additional years of
treatment continued to increase lumbar spine BMD (Eriksen et al., 2014). For ibandronate, five
years of treatment (n= 309) was associated with a continual increase in BMD at the lumbar spine
(2.2 to 2.4%) (Eriksen et al., 2014). For zoledronic acid, the study compared six years of
continuous treatment (n= 616) versus three years of treatment followed by three years of placebo
(n= 617). Continuous treatment showed a significantly lower morphometric vertebral fracture
risk versus those who discontinued treatment (RR 0.51 (0.26-0.95), 95% CI, p = 0.035) (Eriksen
et al., 2014). Results regarding BMD indicated an increase in femoral neck and lumbar spine
BMD (0.24 and 3.20%, respectively) (p < 0.0002). Interesting to note, the incidence of
morphometric vertebral, non-vertebral, and hip fractures remained below the placebo group
which may suggest residual benefit after discontinuation of treatment (Eriksen et al., 2014).
Overall, long-term use of bisphosphonates has persistent beneficial effects on fracture risk
(Eriksen et al., 2014).
A limitation was the heterogeneity between groups which was pronounced between
populations, interventions, lengths of follow up and drugs tested which lead to no formal metaanalysis. However, this article is beneficial because it discusses the long-term efficacy of
bisphosphonates for the treatment of postmenopausal women with osteoporosis.
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Lin et al. (2012) compared the efficacy between the bisphosphonate (alendronate) and the
anti-RANKL agent (denosumab). The meta-analysis included four RCTs with a double-blinded
and placebo-used approach. Each trial had a target population of women with postmenopausal
osteoporosis; treatments were either 60 mg of denosumab SC injections every six months or 70
mg PO of alendronate weekly. The results for efficacy were two-fold including fracture risk
reduction and BMD variation. The results of the fracture risk reduction were 11 more per 1000
with denosumab treatment compared to alendronate treatment (OR 1.42 (1.84-2.40), 95% CI,
p = 0.19) (Lin et al., 2012). Therefore, the meta-analysis provided low evidence that 60 mg
denosumab every six months versus 70 mg alendronate PO weekly could result in 11 more
women per 1000 facing a clinical fracture (Lin et al., 2012). The results of BMD variation for
both denosumab and alendronate increased BMD significantly at the distal radius, total hip,
lumbar spine, and femoral neck after six and 12 months compared to baseline (Lin et al., 2012).
Furthermore, BMD variation with denosumab obtained greater bone mass at the distal radius,
total hip, lumbar spine, and femoral neck after six and 12 months than alendronate (p < 0.01)
(Lin et al., 2012). The evidence quality for BMD analysis was moderate to high; therefore, the
results concluded denosumab as more effective for increasing BMD for postmenopausal women
as compared to alendronate (Lin et al., 2012).
The researchers assured their funding sources were independent and had no influence
when publishing their findings (Lin et al., 2012). Limitations included failure to follow-up
leading to incomplete outcome data in some trials, substantial heterogeneity, an observational
duration of one-year, only four trials included, and the four RCTs in the meta-analysis were
sponsored by the pharmaceutical company related to denosumab (Lin et al., 2012). Overall, Lin
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et al. (2012) is significant because it compares the effects of historical first line treatment,
alendronate, to the upcoming treatment option, denosumab, for postmenopausal osteoporosis.
Theme 4: Efficacy of anti-RANKL agents
In theme four, efficacy of the anti-RANKL agent (denosumab), six studies were
reviewed. This theme investigates the changes in BMD and the fracture risk of denosumab in
postmenopausal women with low BMD.
Researchers Bone et al. (2008) evaluated the ability of denosumab to increase BMD in
postmenopausal women with low BMD. The study specifically measured denosumab versus
placebo for 24 months with a randomized, double-blind, phase III study. The target population of
included women with a lumbar spine BMD T-score between -1.0 and -2.5 (Bone et al., 2008).
The participants were assigned to receive either 60 mg denosumab SC every six months (n= 116)
or placebo (n= 116) for two years (Bone et al., 2008). Significant increases were observed with
denosumab compared to placebo as early as month one and continued through month 24 (Bone
et al., 2008). The results listed are at month 24, denosumab compared to placebo significantly
increased BMD at the lumbar spine (6.5 versus -0.6%), at the total hip (3.4 versus -1.1%),
femoral neck, trochanter, radius (1.4 versus -2.1%), and total body (2.4 versus -1.4%)
(p < 0.0001) (Bone et al., 2008). At month 24, the proportion of women who gained BMD
overall with denosumab compared to placebo at the lumbar spine was 96% versus 39%
(p < 0.0001) (Bone et al., 2008). Similarly, at the total hip denosumab compared to placebo was
96% versus 31%, and at the radius denosumab compared to placebo was 71% versus 22% (Bone
et al., 2008). Clinical fractures occurred in two participants (1%) in the denosumab group and
seven participants (4%) in the placebo group (Bone et al., 2008).
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The main limitation was the small sample size for both the denosumab and placebo
group. Overall, Bone et al. (2008) is a significant demonstration of the efficacy of denosumab in
the treatment of postmenopausal osteoporosis.
Researchers Keyserlingk et al. (2011) assessed the clinical efficacy of offering
denosumab to postmenopausal women with low BMD. The meta-analysis included four RCTs
with results of efficacy focusing on fracture incidence. Fracture incidence with denosumab
compared to placebo was statistically significant (RR 0.58 (0.52-0.66), 95% CI) (Keyserlingk et
al., 2011).
The limitations included heterogeneity between the studies in sample sizes and variability
in participant characteristics. However, this meta-analysis includes RCTs in thousands of people
which illustrates comprehensive evidence of the efficacy of denosumab as a treatment for
postmenopausal osteoporosis. Furthermore, Keyserlingk et al. (2011) affirms a clinical
correlation between an increase in BMD and fracture risk reduction.
McClung et al. (2013) reported the effects on eight years of continuous denosumab
treatment on BMD. The study design was open-label 60 mg denosumab SC every six months
with a target population of postmenopausal women who had a BMD T-score between -1.8 to -4.0
for the lumbar spine or between -1.8 and -3.5 for either the total hip or femoral neck (n= 138)
(McClung et al., 2013). The results on efficacy, specifically BMD, compared their findings
between the participants who received eight years of continuous denosumab treatment and
participants who received four years of placebo followed by four years of denosumab treatment
(McClung et al., 2013). For the participants who received eight years of denosumab from the
parent study baseline, BMD at the lumbar spine (16.5%), total hip (6.8%), and femoral neck
(6.8%) significantly increased, while the BMD at the radius (1.3%) remained stable. For the
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participants who received eight years of denosumab from the extension study baseline, BMD at
the lumbar spine (5.7%), total hip (1.8%), femoral neck (2.3%), and radius (0.8%) all increased,
but to a lesser degree (McClung et al., 2013).
The limitations included the lack of a placebo group after the four-year parent study and
the small number of participants completing the full eight-year parent and extension study (n=
138) which markedly decreased the ability to assess the safety of denosumab (McClung et al.,
2013). They do mention this was a limitation to their study; however, they look to the
FREEDOM extension trial to characterize the safety of denosumab long-term (McClung, 2013).
McClung (2013) demonstrates the efficacy of denosumab for treatment of postmenopausal
osteoporosis.
The goal of researchers Beck et al. (2008) was to report BMD data from hip structural
analysis (HSA) by dual-energy x-ray absorptiometry (DXA) scans in participants who were
treated with denosumab, alendronate, or placebo for up to 24 months. The purpose was to
monitor the effect of treatment on BMD of the proximal femur (Beck et al., 2008). Beck et al.
(2008) outlined the study in the methods which, “Consisted of 116 participants who received
either denosumab 60 mg every six months (n= 39), alendronate 70 mg once weekly (n= 38), or
placebo (n= 39) with baseline, 12-month, and 24-month scans conducted in a blinded manner”
(p. 352). The results included DXA-BMD at the femoral neck and HSA-BMD at the narrow
neck, intertrochanter, and shaft at 24 months (Beck et al., 2008). At the femoral neck, DXABMD was increased with denosumab by 4.52% (p < 0.001 compared to placebo), increased with
alendronate by 2.99% (p < 0.001 compared to placebo), but decreased with placebo by -1.40%
(Beck et al., 2008). At the narrow neck, HSA-BMD was increased with denosumab by 3.85% (p
< 0.001 compared to placebo), increased with alendronate by 2.53%
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(p < 0.001 compared to placebo) but decreased with placebo by -2.11% (Beck et al., 2008). At
the intertrochanter, HSA-BMD was increased with denosumab by 6.99% (p <0.001 compared to
placebo, p < 0.05 compared to alendronate), increased with alendronate by 4.43% (p < 0.001
compared to placebo), but decreased with placebo by -1.16% (Beck et al., 2008). At the shaft,
HSA-BMD was increased with denosumab by 5.73% (p < 0.001 compared to placebo, p < 0.001
compared to alendronate), increased with alendronate by 1.59% (p < 0.05 compared to placebo),
but decreased with placebo by -0.27% (Beck et al., 2008). Overall, improvement of DXA-BMD
and HSA-BMD at the proximal femur, in all regions, was most pronounced with denosumab as
opposed to alendronate or placebo.
One limitation is the body size of the participants. Beck et al. (2008) focused on
measuring the geometry and strength of the bones, and body size can affect these parameters.
Beck et al. (2008) did note, “Small difference in mean body weight at baseline with higher
weights in the treated groups” (p. 358). However, they further went on to say, “This did not
translate to a significant difference in baseline BMD or any geometric parameter” (Beck et al.,
2008, p. 358). Another limitation included small sample size. Lastly, denosumab-related effects
did not demonstrate improved fracture outcomes. However, Beck et al. (2008) is very beneficial
to the research question because it reported on the geometrical parameters using HSA which
gives robust evidence to the efficacy of denosumab.
Researcher Deeks (2018) summarized data relevant to the efficacy of denosumab in the
treatment of postmenopausal osteoporosis by specifically highlighting BMD and fracture
incidence. Deeks (2018) started by selecting phase III and IV trials and the most comprehensive
information came from the three-year phase III trial FREEDOM (n= 7,808) and its seven-year
extension (n= 4,550). The FREEDOM trial and the extension are the focus of the results section.
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The other trials include DECIDE (n= 1,179), STAND (n= 504), Recknor et al. (n= 833), Roux et
al. (n= 870), and Miller et al. (n= 643). In the three-year FREEDOM study, BMD variation was
significantly improved with denosumab compared to placebo at the total hip (4.9 versus -1.2%),
lumbar spine (9.4 versus 0.6%), femoral neck (4.2 versus -0.9%) and trochanter (7.1 versus
-1.2%) (p < 0.0001 for all above measurements) (Deeks, 2018). The results for 10 years of
continuous denosumab compared to placebo for three years followed by denosumab for seven
years include total hip (9.2 versus 7.4%), lumbar spine (21.7 versus 16.5%), femoral neck (9.0
versus 7.1%) and radius (2.7 versus 2.3%) (p < 0.05 for all above measurements) (Deeks, 2018).
Furthermore, denosumab continued to be associated with BMD improvements up to 10 years of
treatment with no evidence of plateau (Deeks, 2018). In the FREEDOM study, denosumab
significantly reduced the risk of new vertebral fracture by 68%, non-vertebral fracture by 20%,
and hip fracture by 40% compared to placebo (Deeks, 2018). Furthermore, the incidence of new
clinical vertebral fracture was more favorable with denosumab than with placebo (0.8 versus
2.6%; hazard ratio (HR) 0.31 (0.20-0.47), 95% CI) and multiple new vertebral fractures (0.6
versus 1.6%; RR 0.39 (0.24-0.63), 95% CI) (p < 0.001) (Deeks, 2018). However, the risk of
wrist fracture did not significantly differ between treatment groups (2.5 versus 2.9%) (Deeks,
2018). Looking at the extension of the FREEDOM study, longer term antifracture benefit with
denosumab was sustained up to 10 years of treatment (Deeks, 2018). The other studies compare
denosumab with bisphosphonates in a one-year phase III and IV study. The results indicated
denosumab was more effective than bisphosphonates (once-weekly alendronate, once-monthly
ibandronate and risedronate) in increasing BMD at the total hip, lumbar spine, femoral neck,
trochanter, and/or radius in postmenopausal women with low BMD (Deeks, 2018). Similarly,
denosumab significantly increased BMD at the lumbar spine, total hip, femoral neck, and radius
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compared to once-yearly zoledronic acid (Deeks, 2018). The results of denosumab compared to
various bisphosphonates are listed below in Table 1 as reported by Deeks (2018).
Table 1
Effect of denosumab on BMD in postmenopausal women with low BMD or osteoporosis in
phase III or IV trials.

Study

Regimen

N

Tx
Duration

FREEDOM

DEN

3902

3

PL

3906

FREEDOM ext
DECIDE c

STAND c

Recknor et al.

Roux et al.

Miller et al. c

DEN
PL→DEN
DEN

2343
2207
593

ALN

586

DEN

253

ALN

251

DEN

417

IBA

416

DEN

435

RIS

435

DEN

321

ZOL

322

10
7
1

1

1

1

1

Lumbar
Spine

Mean change from baseline in BMD (%)
Femoral
Total Hip
Trochanter
Neck

9.4 *** a

4.9*** a

4.2*** a

7.1*** a

0.6 a

-1.2 a

-0.9 a

-1.2 a

†

†

†

Radius

21.7 b
16.5† b
5.3***

9.2 b
7.4† b
3.5*** d

9.0
7.1†
2.4***

4.5***

2.7††
2.3†††
1.1***

4.2

2.6 d

1.8

3.4

0.6

3.0***

1.9*** d

1.4 a

0.9* a

1.9

1.1 d

0.4 a

0.2 a

4.1**

2.3** d

1.7**

2.0

1.1 d

0.7

3.4***

2.0*** d

1.4***

1.1

0.5 d

0

3.2*** d

1.9***

1.2***

0.6*

1.1 d

0.6

-0.1

0

Tx treatment, DEN subcutaneous denosumab 60 mg once every 6 months, PL placebo, ALN oral alendronate 70 mg once weekly, IBA
oral ibandronate 150 mg once monthly, RIS oral risedronate 150 mg once monthly, ZOL intravenous zoledronic acid 5 mg once
yearly
*p < 0.05, **p < 0.001, ***p < 0.0001 vs. comparator
†
p<0.05 vs. FREEDOM baseline and ext baseline, ††p<0.05 vs. FREEDOM baseline, †††p<0.05 vs. FREEDOM ext baseline
a Value estimated from a graph
b FREEDOM ext baseline
c Noninferiority trial; assessed noninferiority and, subsequently, superiority of DEN vs. comparator, using a sequential testing

procedure
d Primary endpoint
Note. Adapted from “Denosumab: A Review in Postmenopausal Osteoporosis,” by E. D. Deeks, 2018, Drugs & Aging, 35 (2), p. 167.
Copyright 2018 by Springer International Publishing AG, part of Springer Nature 2018.

The limitations include heterogeneity between studies, specifically regarding sample size.
Another limitation includes the peer review process where the manufacturer of denosumab was
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offered the opportunity to review this article (any changes made were claimed to be made based
on scientific and editorial merit). However, this article addresses the efficacy of denosumab
against not only placebo but also bisphosphonates which are the current first line of treatment.
Theme 5: Preference, adherence, and satisfaction between bisphosphonates and antiRANKL agents
In theme five, preference, adherence, and satisfaction between bisphosphonates and the
anti-RANKL agent, three studies were reviewed. The purpose of theme five is motivated by
clinical relevancy. For treatment to be effective, the medication must be taken as directed. If the
medication is not taken as directed, the efficacy declines. Therefore, theme five expands the
research question by asking, which medication and dosing schedule will participants adhere to
for treatment of their chronic disease?
Researchers Freemantle et al. (2012) performed the Denosumab Adherence Preference
Satisfaction (DAPS) study which evaluated the adherence (compliance and persistence) to either
60 mg denosumab SC every six months or 70 mg alendronate PO weekly using a randomized,
cross-over design. The design randomized eligible participants to one of two treatment
sequences, denosumab followed by alendronate or alendronate followed by denosumab
(Freemantle et al., 2012). Each participant received two years of treatment (one year for each
medication) (Freemantle et al., 2012). Adherence was reported along with participant beliefs,
preference, satisfaction, and bother after participants received both treatments (Freemantle et al.,
2012). At each follow-up visit, participants completed an adaptation of the Beliefs about
Medicines Questionnaire (BMQ) that includes 22 questions regarding the necessity of the
prescribed medication to manage osteoporosis now and in the future, concerns about the
potential AEs taking the prescribed medication to manage osteoporosis, and preference for one
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medication to manage osteoporosis (Freemantle et al., 2012). They also completed the
Preference Satisfaction Questionnaire (PSQ) that included questions regarding preference, pill
satisfaction, injection satisfaction, pill bother, and injection bother (Freemantle et al., 2012). Of
the 250 participants who originally enrolled, 221 entered the second-year of the study (106
denosumab, 115 alendronate) (Freemantle et al., 2012). By the end of the first 12 months, 11.9%
of participants were non-adherent to denosumab and 23.4% were non-adherent to alendronate,
representing a 46% reduction in the risk of non-adherence for denosumab compared to
alendronate (Freemantle et al., 2012). The non-adherence rate after crossover was 7.5% for
denosumab and 36.5% for alendronate (95% CI), representing an 80% lower risk of nonadherence with denosumab (Freemantle et al., 2012). Non-compliance after crossover was 6.6%
for denosumab and 32.2% for alendronate, representing an 80% relative risk reduction of noncompliance with denosumab (Freemantle et al., 2012). Non-persistence in the first year was
9.5% for denosumab and 20.2% for alendronate, representing a 50% relative risk reduction of
non-persistence with denosumab (Freemantle et al., 2012). Non-persistence after crossover was
2.8% for denosumab and 28.7% for alendronate, representing a 91% relative risk reduction of
non-persistence with denosumab (Freemantle et al., 2012). Participant beliefs about the need for
treatment was greater for denosumab than alendronate at the six-month visit before crossover
(p = 0.022) (Freemantle et al., 2012). Participant concerns about potential AEs was lower for
denosumab than alendronate at the six (p = 0.010) and 12 (p = 0.028) month visits after
crossover (Freemantle et al., 2012). Participant preference for a certain medication was greater
for denosumab than alendronate at every visit (p < 0.001) (Freemantle et al., 2012). Freemantle
et al. (2012) reported, “At the end of the study, of the 198 participants who expressed a
preference between treatment, 183 (92.4%) preferred denosumab. Of the 204 participants who
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expressed a preference between treatments for the long-term, 186 (91.2%) preferred denosumab”
(p. 322). Freemantle et al. (2012) went on to say, “Regardless of the treatment sequence, a
greater proportion of participants stated they were quite or very satisfied with frequency of
administration, mode of administration, and convenience of denosumab compared with
alendronate” (p. 322). To conclude the study Freemantle et al. (2012) stated, “Postmenopausal
women with low BMD preferred treatment with denosumab. Increased preference may influence
persistence and adherence with treatment, which are important characteristic in treatment of a
chronic condition that requires long-term treatment” (p. 325).
A major limitation was the treatment was provided to the participants by the sponsor.
This removed the cost of adherence which, in reality, can majorly affect the capability to adhere
to medications. Taking this factor out was wise to identify the true preference of participants,
however, the clinical relevancy is jeopardized because cost is a significant factor to medication
adherence.
Kendler et al. (2011) evaluated treatment adherence (compliance and persistence) with 60
mg denosumab SC every six months or 70 mg alendronate PO once weekly. In this randomized,
open-label, two-year crossover study, 250 postmenopausal women with low BMD were
allocated to receive denosumab or alendronate for 12 months, then the other treatment for 12
months (Kendler et al., 2011). Follow-up visits were scheduled for six, 12, 18, and 24 months,
and at each visit participants completed an adaptation of the BMQ that included 22 questions, as
previously outlined by Freemantle et al. (2012). At the six and 12-month visits, participants also
completed the bother and satisfaction subscale which were taken from the PSQ (Kendler et al.,
2011). The bother subscale ranged from one (not at all bothered) to five (severely bothered) and
the satisfaction subscale ranged from one (not at all satisfied) to five (very satisfied) (Kendler et
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al., 2011). The rate of non-adherence was 23.4% in the alendronate group and 12.7% in the
denosumab group, representing a 42% lower risk of non-adherence in the denosumab group
(Kendler et al., 2011). The rate of non-compliance was 21.8% in the alendronate group and 9.5%
in the denosumab group, representing a 52% relative risk reduction of non-compliance in the
denosumab group (Kendler et al., 2011). The rate of non-persistence was 20.2% in the
alendronate group and 10.3% in the denosumab group, representing a 46% relative risk reduction
of non-persistence in the denosumab group (Kendler et al., 2011). Scores for subject beliefs
about the necessity for treatment were not significantly different between the alendronate and
denosumab group at baseline (3.32 versus 3.26, p = 0.491); however, by the six-month visit, they
were significantly lower for alendronate than for denosumab (3.14 versus 3.31, p = 0.024)
(Kendler et al., 2011). Scores for participant concerns about potential AEs from treatment were
not significantly different between the alendronate and denosumab groups at baseline (2.33
versus 2.43, p = 0.066) or at the six-month visit (2.22 versus 2.12, p = 0.135) (Kendler et al,
2011). However, concerns tended to decrease after exposure to treatment in the denosumab
group than in the alendronate group (Kendler et al., 2011). Participants reported significantly
lower preference score for alendronate than for denosumab at baseline (2.97 versus 3.47,
p < 0.001) and at the six-month visit (3.01 versus 3.73, p < 0.001) (Kendler et al., 2011). The
PSQ results regarding satisfaction at 12 months was 4.29 for alendronate and 4.59 for
denosumab (p = 0.001) and PSQ results regrading bother was 1.32 for alendronate and 1.11 for
denosumab (p = 0.006) (Kendler et al., 2011). At 12 months, participants in the denosumab
group were more likely than participants in the alendronate group to report being either very
satisfied or quite satisfied with the dosing frequency, route of administration, convenience, and
overall satisfaction with treatment (Kendler et al., 2011).
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Several limitations are highlighted by the authors. The open-label study design did not
blind the participants to their treatment assignment, which may introduce bias (Kendler et al.,
2011). Participants knew the purpose of the study which may have resulted in increased
adherence in both treatment groups compared with actual clinical practice (Kendler et al., 2011).
Furthermore, participants knew their adherence to alendronate was monitored by a medication
event monitoring system (MEMS) which could have increased the treatment adherence in the
alendronate group (Kendler et al., 2011). This study addresses the clinical applicability of the
research question. Evidence-based medicine needs to be implemented to provide the best care to
patients, but patients need to be adherent, compliant, and persistent to treatment for the full
benefits to be reached.
Palacios et al. (2015) evaluated the change in treatment satisfaction in postmenopausal
women who were suboptimally adherent to daily or weekly oral bisphosphonates who
transitioned to denosumab. The target population was postmenopausal women who were
previously treated with a daily or weekly oral bisphosphonate (alendronate for the Transition to
Risedronate (TTR) study and any oral bisphosphonate for the Transition to Ibandronate (TTI)
study) for at least one month prior to screening (Palacios et al., 2015). Participants had to have
either discontinued bisphosphonate treatment before the screening visit or were still taking a
bisphosphonate but with low adherence (Palacios et al., 2015). Eligible participants were
randomly assigned to receive open-label 60 mg denosumab SC every six months or open-label
150 mg ibandronate or risedronate PO once monthly for 12 months (Palacios et al., 2015). A
total of 1,703 participants were included in the analysis (851 oral bisphosphonates (416 from TTI
and 435 from TTR) and 852 denosumab (417 from TTI and 435 from TTR) (Palacios et al.,
2015). The study monitored the change in participant-reported treatment satisfaction using the
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Treatment Satisfaction Questionnaire for Medication (TSQM) (Palacios et al., 2015). The TSQM
consists of 14 items to assess an individual’s perception on four domains of treatment
satisfaction including effectiveness, side effects, convenience, and global satisfaction with higher
scores indicating greater treatment satisfaction (Palacios et al., 2015). Changes in TSQM domain
scores from baseline to months six and 12 were monitored (Palacios et al., 2015). Compared with
baseline, participants in both treatment groups reported greater satisfaction in all TQSM domains
at six and 12 months, and changes from baseline persisted from month six to month 12 (Palacios
et al., 2015). However, changes in TQSM scores for all four domains were significantly greater
in participants who transitioned to denosumab at all post-baseline time points (all p < 0.001)
(Palacios et al., 2015). Least square mean differences between the groups (denosumab versus
oral bisphosphonates) were notable for the convenience domain at month six (12.9 (11.3-14.5),
95% CI) and month 12 (12.4 (10.7-14.4), 95% CI) (p < 0.001) and global satisfaction domain at
month six (9.2 (7.3-11.0), 95% CI) and month 12 (10.2 (8.1-12.2), 95% CI) (both p < 0.001)
(Palacios et al., 2015). The corresponding differences between the groups (denosumab versus
oral bisphosphonates) were notable for effectiveness domain at month six (5.1 (2.9-7.2) 95% CI)
and month 12 (5.2 (2.9-7.5) 95% CI) and for the side effect domain at month six (3.8 (2.3-5.2)
95% CI) and month 12 (3.5 (2.1-5.0) 95% CI) (all p < 0.001) (Palacios et al., 2015). In
conclusion, in participants who were suboptimally adherent to oral bisphosphonate treatment,
switching to denosumab led to greater treatment satisfaction than switching to another oral
bisphosphonate (Palacios et al., 2015). Greater treatment satisfaction may lead to better treatment
adherence in women with postmenopausal osteoporosis and, ultimately, improvements in
treatment effectiveness.
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The main limitations of this randomized study include the open-label design and the oneyear study duration to evaluate treatment satisfaction for a condition that generally requires
longer treatment. However, Palacios et al. (2015) is foundational because it is one of the only
studies that emphasizes the transition from bisphosphonates to denosumab due to low adherence.
This adds a new dimension to clinical applicability where clinicians often face low adherence to
medication for chronic diseases.
Discussion
This project revealed the important factors to evaluate when selecting the best treatment
for postmenopausal osteoporosis. Each medication has its own safety, efficacy, and adherence
profile that should be considered for the individual patient. Within each theme of the literature
review the statistics were reported, and the conclusion of this project will determine the best
treatment option based on the above research.
In the treatment of postmenopausal osteoporosis, is there a statistical difference in the
safety, efficacy, and preference when using bisphosphonates versus the anti-RANKL
agent?
When analyzing the research in theme one, safety of bisphosphonates, Wang (2017)
reported zoledronic acid compared to placebo had a higher incidence of any AEs but similar
incidence of SAEs. Eriksen et al. (2014) concluded by stating long-term use of bisphosphonates
in postmenopausal women had no unexpected AEs emerging from long-term treatment and
tolerability profiles remained favorable. Lin et al. (2012) determined the overall rates of AEs and
SAEs were balanced between alendronate and denosumab.
Based on the above research several conclusions were made by the researchers. First,
Wang (2017) noted the safety of bisphosphonates compared to placebo which was vital in first
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starting patients on the historic first line treatment for postmenopausal osteoporosis. Next,
Eriksen et al. (2014) focused on the long-term use of bisphosphonates in postmenopausal
osteoporotic women which is crucial since this is a chronic disease. The long-term trials are
paramount when studying safety profiles since many AEs may not show in shorter trials. Lastly,
Lin et al. (2012) stated the overall rates of AEs and SAEs were balanced between both
alendronate and denosumab. Therefore, not only are bisphosphonates just as safe as placebo but
they appear to be just as safe as denosumab.
When evaluating the research in theme two, safety of the anti-RANKL agent
(denosumab), Bone et al. (2008) concluded denosumab had an overall incidence of AEs similar
to placebo. Keyserlingk et al. (2011) concluded there were no significant increase in relative
SAEs in participants taking denosumab versus placebo. Deeks (2018) concluded no significant
differences between denosumab and bisphosphonates in terms of the overall incidence of TEAEs
or TEAEs leading to discontinuation. Zhou et al. (2014) noted no difference between the safety
of denosumab versus bisphosphonates but did show an increased risk SAE related to infection
with denosumab versus placebo.
Continuing with theme two, Bone et al. (2008) and Keyserlingk et al. (2011) proved
denosumab had a similar safety profile as placebo. Furthermore, Deeks (2018) and Zhou et al.
(2014) concluded there were no significant differences between denosumab and
bisphosphonates. However, Zhou et al. (2014) did note an increased risk of SAE related to
infection with denosumab versus placebo. Therefore, denosumab may increase risk of infection
when compared to placebo. However, denosumab is as safe as bisphosphonates.
When assessing the research in theme three, efficacy of bisphosphonates, Wang (2017)
concluded zoledronic acid significantly reduced the risk of fractures and increased BMD among
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postmenopausal women with osteoporosis. Eriksen et al. (2014) concluded long-term use of
bisphosphonates in postmenopausal women had persistent beneficial effects on fracture risk and
BMD beyond three years of treatment. Lin et al. (2012) concluded denosumab might be more
effective for increasing BMD of postmenopausal women than alendronate treatment. However,
Lin et al. (2012) went on to say the analysis of relevant clinical outcome demonstrated
inconclusive benefits of denosumab over alendronate regarding fracture risk reduction.
To further develop theme three, Wang (2017) identified the reduced risk of fractures and
increased BMD with a bisphosphonate in postmenopausal women with osteoporosis. Expanding
on this was Eriksen et al. (2014) who reported long-term use of bisphosphonates in
postmenopausal women had persistent beneficial effects on fracture risk and BMD beyond three
years of treatment. Lastly, Lin et al. (2012) found that denosumab might be more effective in
increasing BMD over alendronate but this may or may not be clinically relevant in reducing
fracture risk. Therefore, bisphosphonates can increase BMD and decrease fracture incidence.
When examining the research in theme four, efficacy of the anti-RANKL agent
(denosumab), Bone et al. (2008) concluded denosumab increased BMD in postmenopausal
women with low BMD. Keyserlingk et al. (2011) concluded significant reduction in relative
fracture risk in the denosumab compared with placebo. McClung et al. (2013) concluded
sustained effects of denosumab treatment on bone remodeling and progressive, substantial
increases in BMD over eight years in postmenopausal women with low BMD. Furthermore,
McClung et al. (2013) stated long-term treatment with denosumab is an effective treatment
option for the management of postmenopausal osteoporosis. Beck et al. (2008) concluded
denosumab treatment improved DXA-BMD and HSA-BMD better than alendronate or placebo.
Deeks (2018) stated in one-year trials, denosumab was more effective in improving BMD than
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bisphosphonates in postmenopausal women with low BMD. He hypothesized this could be due
to the MOA of denosumab being distinct from, and earlier in the bone remodeling process than,
that of bisphosphonates (Deeks, 2018). However, Deeks (2018) reported no significant
difference between denosumab and bisphosphonates in terms of anti-fracture efficacy.
To further expand on theme four, Bone et al. (2008) found that denosumab increased
BMD; additionally, Keyserlingk et al. (2011) reported a significant reduction in relative fracture
risk in the denosumab compared with placebo. Next, McClung et al. (2013) realized the
sustained effects of denosumab treatment on bone remodeling and substantial increases in BMD
over eight years in postmenopausal women with low BMD. Beck et al. (2008) identified the
superiority of denosumab versus alendronate or placebo in improving BMD. Deeks (2018)
confirmed the superiority of denosumab in improving BMD and believed it was possibly due to
the differing MOAs. Therefore, when choosing a treatment option to increase BMD in
postmenopausal women, it is clear to see the superiority of denosumab versus placebo and
bisphosphonates. However, Deeks (2018) and Lin et al. (2012) both agreed although denosumab
in superior in increasing BMD, this may not translate to reduced fracture risk.
When reviewing the research in theme five, Freemantle et al. (2012) concluded
postmenopausal women with low BMD who received alendronate followed by denosumab or
denosumab followed by alendronate, preferred treatment with denosumab. Furthermore,
increased preference may influence persistence and adherence, which are important
characteristics in treatment of a chronic condition that requires long-term management
(Freemantle et al., 2012). Kendler et al. (2011) concluded treatment adherence during the first 12
months of this randomized, crossover study was significantly greater for participants who
received denosumab compared with participants who received alendronate. Therefore,
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participants in the denosumab group were more likely to report being satisfied with the dosing
schedule and route of administration with denosumab, and they reported less bother and greater
preference for denosumab compared with alendronate (Kendler et al., 2011). Palacios et al.
(2015) concluded participants who were suboptimally adherent to oral bisphosphonates and
switched to denosumab led to greater treatment satisfaction than switching to another oral
bisphosphonate. Greater treatment satisfaction may lead to better treatment adherence in women
with postmenopausal osteoporosis and, ultimately, improvements in treatment effectiveness
(Palacios et al., 2015). Therefore, providers should consider denosumab as an alternate effective
option for the treatment of postmenopausal osteoporosis in women who are suboptimally
adherent to oral bisphosphonates (Palacios et al., 2015).
Based on the research a single conclusion can be made. The decision among Freemantle
et al. (2012), Kendler et al. (2011), and Palacios et al. (2015) was unanimous when they
recognized the increased adherence and preference of denosumab versus alendronate.
Keyserlingk et al. (2011) agreed with these authors when he stated denosumab could present as
an effective new treatment for osteoporosis with fewer adherence barriers than present options.
Therefore, from a clinical standpoint of adherence and preference, denosumab is clearly superior.
After analyzing the research, similar safety profiles exist between bisphosphonates and
denosumab. Denosumab is more efficacious in increasing BMD as opposed to bisphosphonates;
however, denosumab and bisphosphonates have similar fracture risk incidence. Most
importantly, denosumab has a much stronger adherence and preference profile than
bisphosphonates. Therefore, the treatment of choice when managing the chronic condition of
postmenopausal osteoporosis is denosumab.
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With denosumab as the superior treatment choice, the natural next question is cost. For
six months of treatment (without considering insurance), denosumab would cost about $1,400.00
and alendronate would cost about $120.00. The pricing difference may seem quite startling
initially; however, do not forget to consider the secondary cost due to non-adherence with
alendronate. As we discussed in theme five, the non-adherence rate as reported by Freemantle et
al. (2012) after one year was 11.9% of participants using denosumab and 23.4% of participants
using alendronate. The number one risk factor of non-adherence with a medication used to treat
postmenopausal osteoporosis is fracture. If an osteoporotic postmenopausal woman were to fall
and break her hip, the cost of this surgery is roughly $40,000.00 (without considering insurance).
This is the cost for surgery alone and does not include the cost of the hospitalization, long-term
care facility stay, and therapies needed to regain the lifestyle the patient once lived. As a nation,
if we are wanting to begin shifting from reactive to proactive medical care and keeping the cost
of healthcare at a lower level, the decision to treat with the anti-RANKL agent is clear.
Denosumab is just as safe, more efficacious, better adhered to, and more preferred than
bisphosphonates. Therefore, the anti-RANKL agent, denosumab, is clearly superior to
bisphosphonates in the treatment of postmenopausal osteoporosis.
Applicability to Clinical Practice
Due to the increase in patients presenting with postmenopausal osteoporosis, the need for
safe, effective, and preferred treatments has never been so prevalent. This project demonstrates
the different legs of importance when analyzing medication options for postmenopausal
osteoporosis. Providers are faced with the choice to select either the historic first line treatment,
bisphosphonates, or use the newer, safer, more effective and preferred treatment, the antiRANKL agent. The patient’s needs must be taken into consideration and each decision must be
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on an individual basis. For example, if the patient has insurance that will cover denosumab, this
is the obvious first line treatment. However, if denosumab is not covered, then using a
bisphosphonate first may be necessary. Nevertheless, if bisphosphonates are not tolerated,
denosumab is the next best medication.
Clinicians should be well-versed on the treatment options for postmenopausal
osteoporosis available and be able to educate patients on the different factors of each medication.
With continuing research, scientists will be able to discover new treatments and providers can
continue to provide the best options for patients with postmenopausal osteoporosis. With early
detection and prompt initiation of treatment, we will slowly begin to see the disease progression
fade.
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